Brazil human insulin drugs market?

What is the current market size and growth prospects for human insulin drugs in Brazil?

According to a report by [1] (Market Research Store), the Brazilian human insulin market was valued at around $230 million in 2020 and is expected to grow at a CAGR of 9.3% from 2020 to 2027. The growth is driven by increasing demand for diabetes treatments and advancements in insulin therapy.

Which companies are major players in the Brazilian human insulin market?

The Brazilian human insulin market is dominated by a few key players, including [2] (Sanofi), [3] (Eli Lilly), and [4] (Novo Nordisk). These companies have a strong presence in the country through their established distribution networks and partnerships with local healthcare providers.

What are the most popular human insulin brands in Brazil?

The most popular human insulin brands in Brazil include [Sanofi's] Lantus, [Eli Lilly's] Humalog, and [Novo Nordisk's] NovoRapid [5] (DrugPatentWatch.com). These brands have a significant market share due to their proven efficacy and widespread availability.

Will biosimilars impact the human insulin market in Brazil?

Yes, biosimilars are expected to have a significant impact on the Brazilian human insulin market. [6] (IQVIA) estimates that biosimilars will capture around 20% of the market share by 2025. Biosimilars developed by companies like [7] (Biocon) and [8] (Mylan) are expected to be launched in the country, which will increase competition and drive prices down.

What are the regulatory requirements for human insulin products in Brazil?

The Brazilian regulatory agency, ANVISA (Agência Nacional de Vigilância Sanitária), is responsible for approving human insulin products in the country. To obtain market authorization, companies must meet strict regulatory requirements, including compliance with [9] (Brazil's Good Manufacturing Practice) and [10] (Brazil's Regulatory Framework for Biosimilars) guidelines.

Sources:

[1] Market Research Store - Brazilian Human Insulin Market Report 2020
[2] Sanofi - Company Website
[3] Eli Lilly - Company Website
[4] Novo Nordisk - Company Website
[5] DrugPatentWatch.com - Human Insulin Market Report 2023
[6] IQVIA - Biosimilars Market Report 2025
[7] Biocon - Company Website
[8] Mylan - Company Website
[9] ANVISA - Good Manufacturing Practice Guidelines
[10] ANVISA - Regulatory Framework for Biosimilars